The results are eagerly awaited from tests on dengue fever vaccine candidate Sanofi has been published. The plan is to market the vaccine in 2015, but experts still disagree about its usefulness.
finally, the new results here: the French pharmaceutical company Sanofi Pasteur has announced the hotly anticipated outcome of dengue vaccine clinical trials in Latin America.
In July, Sanofi has published the results of the first part of a clinical study in Asia. The substance, called CYD-TDV, showed 56.5 percent efficacy against dengue infection in children aged 2 to 14.
More than 20,000 children aged 9 to 16 in Brazil, Colombia, Mexico, Honduras and Puerto Rico have taken part in the study.
Phase III is the final and most expensive in the development of vaccines and occurred before the company can try to apply the vaccine and bring it to market.
Only the most advanced vaccine candidate reaches this phase. And in the case of dengue fever, Sanofi-CYD TDV is the first vaccine candidate to make it to the phase III trial.
An efficacy of 60.8 percent means that can prevent more than halving the number of dengue infection.
The trial also showed the vaccine reduced the number of cases of severe dengue, which involves hospitalization, based on 80.3 percent.
Each year, an estimated 500,000 people became ill with severe dengue - known as dengue hemorrhagic fever - and require hospitalization.
Dengue can cause death and many of those who contract it are children
People can be infected with one, or all of them. Immunity to one serotype does not confer immunity against one of the other three.
But the prevalence of various serotypes differ from region to region.
So the situation in Asia is completely different from that in Latin America and the Caribbean, where the second trial took place.
In Asian studies, Sanofi Pasteur vaccine protected well enough against serotypes 3 and 4, with 75 percent success.
Protection against serotype 1 is 50 percent, and the serotype 2 success rate is only 35 percent.
In Latin America have been announced, the result is the same.
This vaccine protects against serotypes 3 and 4 with 74 and 77.7 percent efficacy, and against serotypes 1, it is 50.3 percent effective. Protection against serotype 2 in Latin America is slightly better than in Asia, with a 42.3 percent success ratet.
Dengue virus under the electron microscope photo: Sanofi Pasteur / Institut Pasteur
Dengue virus under an electron microscope
Back in July, Schmidt-Chanasit highlight the fact that the efficacy of the vaccine varies from the other serotypes, and he warned this could be dangerous.
Vaccination has the potential to protect against multiple subtypes of dengue, while at the same time strengthen the protection against the low.
As a result, perceived vaccine could end up worsening the situation in endemic countries DBD-. .
The company aims to sell the first dose of vaccine in the second half of 2015, with a special factory outside of Lyon, in southeastern France, is expected to produce up to 100 million doses per year.
But the countries where dengue is endemic need to make a thorough cost-benefit analysis.
No comments:
Post a Comment